pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·1d ago·1 min read
save

FDA to refer to AI as ‘super intelligence’ going forward

Nov 17, 2026·read at raps ↗

The US Food and Drug Administration (FDA) announced that, as of Monday, it will use the term “super intelligence” instead of “artificial intelligence” in all official correspondence, public communications, websites, reports, and policy documents.

source

Reporting by raps.

read at raps ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1d agoRegulators, industry experts look to streamline EU combination product oversightraps
  • 1d agoNew FDA MAPP sheds light on clinical pharmacology reviewsraps
  • 1d agoRecon: FDA approves Roche’s oral SERD for late-stage breast cancer; Lilly strikes up to $5.9B cancer deal with Stipple Bioraps
  • 2d agoAsia-Pacific Roundup: TGA seeks feedback on including UDIs with medical device certificates of free saleraps
  • 2d agoIndustry groups seek clarifications in FDA’s ANDA and 505(b)(2) guidanceraps